Copertina

Editorial: DoesESWL‐ERCPfor pancreatic duct stone removal change the natural course of symptomatic chronic calcific pancreatitis? Authors' reply

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Yu Liu, Liang‐Hao Hu
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Editorial: DoesESWL‐ERCPfor pancreatic duct stone removal change the natural course of symptomatic chronic calcific pancreatitis?
di: Richard Kozarek
Pubblicazione: (2024)

Long‐term clinical outcomes of extracorporeal shockwave lithotripsy and endoscopic retrograde cholangiopancreatography for pancreatic duct stone treatment in patients with chronic pancreatitis
di: Yu Liu, et al.
Pubblicazione: (2024)

Editorial: Quantity is important! Authors' reply
di: Marika Rudler, et al.
Pubblicazione: (2024)

Editorial: Shorter course of intravenous terlipressin in acute variceal bleeding—the promise, controversies and future directions. Author's reply
di: Sagnik Biswas, et al.
Pubblicazione: (2024)

Editorial: Another brick in the CDST wall: Authors' reply
di: Kyuwon Kim, et al.
Pubblicazione: (2024)

Editorial: Crystalising the burden of steatotic liver disease—Authors' reply
di: Carolin V. Schneider, et al.
Pubblicazione: (2024)

Editorial: Recompensation in PBC is good. But is it good enough? Authors' reply
di: Benedikt Silvester Hofer, et al.
Pubblicazione: (2024)

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B—Author's reply
di: Hyeyeon Hong, et al.
Pubblicazione: (2024)

Letter: Potential impact ofHelicobacter pyloriinfection on oesophageal disorders in chronic liver disease—Authors' reply
di: Francisco Idalsoaga, et al.
Pubblicazione: (2024)

Editorial: The microbiome and gastric mucosal protection in aspirin users—Authors' reply
di: Nina Løn, et al.
Pubblicazione: (2024)

Editorial: Can we predict or not predict response to hypnotherapy? That is the question. Authors' reply
di: Dipesh H. Vasant, et al.
Pubblicazione: (2024)

Editorial: Revisit the causes and long‐term outcomes in cirrhosis patients—Authors' reply
di: Linda Henry, et al.
Pubblicazione: (2024)

Editorial: How does the risk of hepatocellular carcinoma change over time in patients with a hepatitis C cure? Authors' reply
di: Philip Vutien, et al.
Pubblicazione: (2024)

Editorial: Unravelling real‐world impact of second‐line therapies in primary biliary cholangitis—Time to change our targets? Authors' reply
di: C. M. Fernández‐Rodríguez, et al.
Pubblicazione: (2024)

Editorial: Genetics for non‐invasive risk stratification—Finding the needle in the haystack? Authors' reply
di: Lana Bridi, et al.
Pubblicazione: (2024)

Editorial: Mortality in immune‐mediated inflammatory diseases during early adulthood—Authors' reply
di: Mikkel Malham, et al.
Pubblicazione: (2024)

Editorial: Sonographic assessment of colonic content—A new tool for constipation? Authors' reply
di: R. M. Mathias, et al.
Pubblicazione: (2024)

Editorial: Emulsifiers and thickeners in our food—Do they alter gut permeability? Authors' reply
di: Jessica A. Fitzpatrick, et al.
Pubblicazione: (2024)

Editorial: High qHBsAg—Is it a good or bad signal? Authors' reply
di: Hsin‐Che Lin, et al.
Pubblicazione: (2024)

Editorial: Hepatitis C virus eradication improves skeletal muscle mass—Authors' reply
di: Marta Paula Pereira Coelho, et al.
Pubblicazione: (2024)

Letter: Irritable bowel syndrome and antibiotics—Authors' reply
di: Kyle Staller, et al.
Pubblicazione: (2024)

Editorial: Mucosal healing with steroids—Once upon a time in ulcerative colitis. Authors' reply
di: Tomohiro Fukuda, et al.
Pubblicazione: (2024)

Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world—Authors' reply
di: Manya Prasad, et al.
Pubblicazione: (2024)

Editorial: Sequencing rescue therapy for acute severe ulcerative colitis—Ready for revision? Authors' reply
di: María José García, et al.
Pubblicazione: (2024)

Editorial: Eosinophilic oesophagitis coming of age—Increasing frequency and wider age range—Authors' reply
di: Akshatha Kiran, et al.
Pubblicazione: (2024)

Editorial: Reading the cholate—A new gateway to portal hypertension and oesophageal varices: Authors' reply
di: Tarek Hassanein, et al.
Pubblicazione: (2024)

Letter: Assessing the Durability of Treatment Effects: Long‐Term Outcomes of ESWL and ERCP for Pancreatic Duct Stones in Chronic Pancreatitis
di: Wei‐Zhen Tang, et al.
Pubblicazione: (2024)

Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice. Authors' reply
di: Eunice X. X. Tan, et al.
Pubblicazione: (2024)

Editorial: Updated epidemiology of steatotic liver disease in people withHIVin the United States—Authors' reply
di: Samer Gawrieh, et al.
Pubblicazione: (2024)

Editorial: Infliximab induction therapy in paediatric Crohn's disease — A cost‐effective strategy? Authors' reply
di: Stephanie A. Vuijk, et al.
Pubblicazione: (2024)

Letter: Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B can increase body weight—Authors' reply
di: Eiichi Ogawa
Pubblicazione: (2024)

Letter: The enigma of angiotensin receptor blocker‐associated enteropathy—Authors' reply
di: Annalisa Schiepatti, et al.
Pubblicazione: (2024)

Editorial: Extending upadacitinib induction dosing in ulcerative colitis—A delicate balance of efficacy and safety. Author's reply
di: Remo Panaccione
Pubblicazione: (2024)

Editorial: Diagnosis of GERD in patients with extra‐oesophageal symptoms—still a long way to go… Authors' reply'
di: Francesco Calabrese, et al.
Pubblicazione: (2024)

Letter: Should ulcerative colitis be monitored more or less invasively? Authors' reply
di: Matthias Lenfant, et al.
Pubblicazione: (2024)

Letter: Thioguanine, an under‐utilised option in inflammatory bowel disease? Authors' reply
di: Abhinav Vasudevan, et al.
Pubblicazione: (2024)

Letter: Modifying the Mayo endoscopic subscore for improved prognostic insights. Authors' reply
di: Matthias Lenfant, et al.
Pubblicazione: (2024)

Letter: Bisphosphonate effectiveness in patients with cirrhosis—an emulated clinical trial. Authors' reply
di: Elliot B. Tapper, et al.
Pubblicazione: (2024)

Letter: Dietary emulsifiers and intestinal health—The beginning of an evolving story: Authors’ reply
di: Jessica A. Fitzpatrick, et al.
Pubblicazione: (2024)

Editorial: Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Prior to Liver Transplantation—Current Evidence and Future Directions. Authors' reply
di: L. Aceituno, et al.
Pubblicazione: (2026)